The use of genomics to understand aging has become a high-profile field in recent months, with J. Craig Venter's Human Longevity and Google's Calico both researching the topic. Now Scripps has given the rest of the sector a new resource--whole genome sequences of 454 healthy elderly people.
The company J. Craig Venter founded in 1998 to challenge the Human Genome Project ran a data center with 70 terabytes of storage. Venter's latest scheme--creating the world's largest sequencing center--will fill that in less than one week.
J. Craig Venter, the aggressively confident gene sequencing and synthetic biology pioneer, is co-founding a new diagnostic and therapeutic startup focused on aging-related diseases. The company, dubbed Human Longevity Inc., rolls out of the starting gate with $70 million in initial investor funding.
Watch out, Google. Genome pioneer Craig Venter, well known for elbowing his way to the front of a scientific race, is launching a new company that will tackle the multitude of diseases that affect aging.
CLC bio wants the world to know that business is good, but the world might be more interested in why its business has taken off. The Danish provider of bioinformatics software touts today that its software sales shot up 30% in 2012 with an equal jump in its number of employees.
After I last wrote about Twitter 's impact on biotech, a few FierceBiotech readers responded with skepticism. They weren't so sure that engaging on a microblogging site was a good use of their...
Geneticist J. Craig Venter's vision for the future of vaccines may seem a little surreal: Making available downloadable software that allows people to print a vaccine and inject it at home.
Computational biology has taken another big leap. The J. Craig Venter and Stanford University have pieced together the first software model of an entire organism, using massive amounts of data and computing power to simulate life processes of the tiny being.
A day after Roche's ($RHHBY) hostile $5.7 billion bid to scoop up Illumina ($ILMN) hit the news, investors are wagering that the maker of DNA sequencing machines will attract a better offer.
Craig Venter is building a new $35 million home for his ambitious work on synthetic biology in San Diego, home to some of the world's most prestigious research institutes. And even his most outspoken